4.6 Letter

Parkinsonism and cognitive impairment following chronic exposure to potassium cyanide

Journal

MOVEMENT DISORDERS
Volume 23, Issue 3, Pages 468-470

Publisher

WILEY
DOI: 10.1002/mds.21871

Keywords

-

Ask authors/readers for more resources

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Clinical Neurology

Giacomo Balla: A Painter in the Context of Neuroscience

Letizia Maria Cupini, Paolo Calabresi

Summary: Giacomo Balla, an Italian Futurist painter, had a profound interest in neurophysiological and neurological sciences, which greatly influenced his personal painting style. His famous artworks serve as historical records of the neuroscience environment at the turn of the 20th century.

NEUROSCIENTIST (2022)

Article Clinical Neurology

Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview

Constance Delaby, Charlotte E. Teunissen, Kaj Blennow, Daniel Alcolea, Ivan Arisi, Elodie Bouaziz Amar, Anne Beaume, Aurelie Bedel, Giovanni Bellomo, Edith Bigot-Corbel, Maria Bjerke, Marie-Celine Blanc-Quintin, Merce Boada, Olivier Bousiges, Miles D. Chapman, Mari L. DeMarco, Mara D'Onofrio, Julien Dumurgier, Diane Dufour-Rainfray, Sebastiaan Engelborghs, Hermann Esselmann, Anne Fogli, Audrey Gabelle, Elisabetta Galloni, Clementine Gondolf, Frederique Grandhomme, Oriol Grau-Rivera, Melanie Hart, Takeshi Ikeuchi, Andreas Jeromin, Kensaku Kasuga, Ashvini Keshavan, Michael Khalil, Peter Koertvelyessy, Agnieszka Kulczynska-Przybik, Jean-Louis Laplanche, Piotr Lewczuk, Qiao-Xin Li, Alberto Lleo, Catherine Malaplate, Marta Marquie, Colin L. Masters, Barbara Mroczko, Leonor Nogueira, Adelina Orellana, Markus Otto, Jean-Baptiste Oudart, Claire Paquet, Federico Paolini Paoletti, Lucilla Parnetti, Armand Perret-Liaudet, Katell Peoc'h, Koen Poesen, Albert Puig-Pijoan, Isabelle Quadrio, Muriel Quillard-Muraine, Benoit Rucheton, Susanna Schraen, Jonathan M. Schott, Leslie M. Shaw, Marc Suarez-Calvet, Magda Tsolaki, Hayrettin Tumani, Chinedu T. Udeh-Momoh, Lucie Vaudran, Marcel M. Verbeek, Federico Verde, Lisa Vermunt, Jonathan Vogelgsang, Jens Wiltfang, Henrik Zetterberg, Sylvain Lehmann

Summary: This study examined the variation in quantifying cerebrospinal fluid (CSF) biomarkers for the diagnosis of Alzheimer's disease (AD) across different centers worldwide and proposed harmonized comments to address inconsistency in interpretation and reporting of results. The findings revealed similarities in (pre-)analytical procedures among centers but significant heterogeneity in cutoff definitions and report comments, leading to the identification of the most accurate and informative comments through consensus for CSF biomarker interpretation in the context of AD diagnosis. This represents the first attempt to propose harmonized reports across specialized laboratories globally involved in AD diagnosis.

ALZHEIMERS & DEMENTIA (2022)

Article Clinical Neurology

Characteristics of subjective cognitive decline associated with amyloid positivity

Olin Janssen, Willemijn J. Jansen, Stephanie J. B. Vos, Merce Boada, Lucilla Parnetti, Tomasz Gabryelewicz, Tormod Fladby, Jose Luis Molinuevo, Sylvia Villeneuve, Jakub Hort, Stephane Epelbaum, Alberto Lleo, Sebastiaan Engelborghs, Wiesje M. van der Flier, Susan Landau, Julius Popp, Anders Wallin, Philip Scheltens, Marcel Olde Rikkert, Peter J. Snyder, Chris Rowe, Gael Chetelat, Agustin Ruiz, Marta Marquie, Elena Chipi, Steffen Wolfsgruber, Michael Heneka, Henning Boecker, Oliver Peters, Jonas Jarholm, Lorena Rami, Adria Tort-Merino, Alexa Pichet Binette, Judes Poirier, Pedro Rosa-Neto, Jiri Cerman, Bruno Dubois, Marc Teichmann, Daniel Alcolea, Juan Fortea, M. Belen Sanchez-Saudinos, Jarith Ebenau, Cornelia Pocnet, Marie Eckerstrom, Louisa Thompson, Victor Villemagne, Rachel Buckley, Samantha Burnham, Marion Delarue, Yvonne Freund-Levi, Asa K. Wallin, Inez Ramakers, Magda Tsolaki, Hilkka Soininen, Harald Hampel, Luiza Spiru, Betty Tijms, Rik Ossenkoppele, Frans R. J. Verhey, Frank Jessen, Pieter Jelle Visser

Summary: In addition to age, setting, and APOE ε4 carriership, specific characteristics of subjective cognitive decline may aid in identifying individuals with amyloid positivity.

ALZHEIMERS & DEMENTIA (2022)

Article Clinical Neurology

PEG-J replacement for duodenal levodopa infusion in Parkinson's disease patients: a retrospective study

Simone Simoni, Pasquale Nigro, Marta Filidei, Giulia Cappelletti, Federico Paolini Paoletti, Danilo Castellani, Mirko Gaggiotti, Lucilla Parnetti, Nicola Tambasco

Summary: This study compares the complications of standard pull and non-endoscopic, radiologic assisted push replacement PEG-J techniques. The results indicate that the push technique has a lower rate of complications, possibly due to a higher replacement turnover acting as a protective factor.

BMC NEUROLOGY (2022)

Article Clinical Neurology

Clinical features and outcome of patients with autoimmune cerebellar ataxia evaluated with the Scale for the Assessment and Rating of Ataxia

Valentina Damato, Claudia Papi, Gregorio Spagni, Amelia Evoli, Gabriella Silvestri, Gianvito Masi, Eleonora Sabatelli, Lucia Campetella, Andrew McKeon, Francesca Andreetta, Vittorio Riso, Gabriele Monte, Marco Luigetti, Guido Primiano, Paolo Calabresi, Raffaele Iorio

Summary: The study evaluated the long-term outcomes of patients with autoimmune cerebellar ataxia, distinguishing between paraneoplastic and non paraneoplastic cases. Neural autoantibodies were detected in a significant portion of patients, with all patients receiving immunotherapy. Patients with paraneoplastic cerebellar syndrome had higher SARA scores compared to idiopathic ACA patients, and those with good outcomes had lower SARA scores.

EUROPEAN JOURNAL OF NEUROLOGY (2022)

Article Pharmacology & Pharmacy

Remission of functional motor symptoms following esketamine administration in a patient with treatment-resistant depression: a single-case report

Lorenzo Moccia, Pierluigi Lanzotti, Maria Pepe, Laura Palumbo, Delfina Janiri, Giovanni Camardese, Anna Rita Bentivoglio, Marco Di Nicola, Paolo Calabresi, Gabriele Sani

Summary: Functional movement disorders (FMD) are abnormal involuntary movements not consistent with neurological diseases. They often co-occur with mood and anxiety disorders and have poor clinical outcomes. This case report presents the successful treatment of FMD symptoms in a patient with treatment-resistant depression (TRD) using esketamine.

INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2022)

Article Clinical Neurology

Mechanical thrombectomy in acute ischemic stroke due to large vessel occlusion in the anterior circulation and low baseline National Institute of Health Stroke Scale score: a multicenter retrospective matched analysis

Andrea Maria Alexandre, Iacopo Valente, Alessandro Pedicelli, Angelo Maria Pezzullo, Francesca Colo, Luca Scarcia, Andrea Romi, Mariangela Piano, Antonio Macera, Joseph Domenico Gabrieli, Giacomo Cester, Antonio Armando Caragliano, Sergio Lucio Vinci, Maria Ruggiero, Christian Commodaro, Andrea Saletti, Guido Andrea Lazzarotti, Mirco Cosottini, Valerio Da Ros, Luigi Bellini, Emilio Lozupone, Adriana Paladini, Valerio Brunetti, Roberta Morosetti, Giovanni Frisullo, Paolo Calabresi, Giacomo Della Marca, Aldobrando Broccolini

Summary: This study evaluated the effectiveness of mechanical thrombectomy in patients with acute ischemic stroke due to large vessel occlusion and baseline mild neurological symptoms. After propensity score matching, patients who received immediate mechanical thrombectomy had a higher chance of excellent outcome at 90 days compared to those who received best medical management/rescue mechanical thrombectomy, with a similar risk of death.

NEUROLOGICAL SCIENCES (2022)

Review Clinical Neurology

Psychiatric symptoms in multiple sclerosis: a biological perspective on synaptic and network dysfunction

Giulia Menculini, Andrea Mancini, Lorenzo Gaetani, Laura Bellingacci, Alfonso Tortorella, Lucilla Parnetti, Massimiliano Di Filippo

Summary: Psychiatric symptoms in multiple sclerosis (MS) are diverse, ranging from clear-cut psychiatric disorders to isolated psychopathological manifestations. These clinical features often go misdiagnosed, receive suboptimal treatment, and are not adequately assessed in disease activity quantification. Pathogenesis of psychiatric symptoms in MS involves emotional reactions to the disability caused by the disease as well as structural damage in the central nervous system. Biological perspective reveals that MS-related psychiatric manifestations are associated with synaptic and neural network dysfunction due to diffuse brain damage from inflammation and neurodegeneration.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2023)

Editorial Material Clinical Neurology

On the Track of a-Synuclein in the Body Skin Biopsies for Diagnosing Synucleinopathies?

Lucilla Parnetti, Giovanni Bellomo

Summary: Multiple system atrophy (MSA) is an aggressive form of synucleinopathy, characterized by misfolded a-syn accumulations mainly in glial cells. Making a clinical diagnosis of MSA is challenging, even for experienced clinicians. Therefore, there is a need for reliable biomarkers to detect the presence and distinguish different synucleinopathies, as disease-modifying treatments are available for some.

NEUROLOGY (2023)

Article Clinical Neurology

Redefinition of dementia care in Italy in the era of amyloid-lowering agents for the treatment of Alzheimer's disease: an expert opinion and practical guideline

Massimo Filippi, Giordano Cecchetti, Annachiara Cagnin, Camillo Marra, Flavio Nobili, Lucilla Parnetti, Federica Agosta

Summary: Currently, no disease-modifying therapies are available for Alzheimer's disease (AD) in Europe. However, evidence from clinical trials suggests that anti-beta amyloid (Aβ) monoclonal antibodies (mAbs) may be authorized for marketing in the near future. A group of prominent AD clinical experts in Italy met to discuss patient selection and management strategies, recognizing the need for significant changes in dementia care to implement disease-modifying therapies. They emphasized the importance of a biological diagnosis using amyloid- and tau-related biomarkers, as well as specialized diagnostic work-up and exclusion criteria assessment by neurology specialists. The experts also proposed a reorganization of dementia and cognitive decline centers into three levels with defined tasks and requirements.

JOURNAL OF NEUROLOGY (2023)

Article Clinical Neurology

CSF Synaptic Biomarkers in AT(N)-Based Subgroups of Lewy Body Disease

Lorenzo Barba, Samir Abu-Rumeileh, Steffen Halbgebauer, Giovanni Bellomo, Federico Paolini Paoletti, Lorenzo Gaetani, Patrick Oeckl, Petra Steinacker, Federico Massa, Lucilla Parnetti, Markus Otto

Summary: This study aimed to investigate the correlation between CSF biomarkers and the presence of AD copathology in LBD patients and determine their usefulness in differentiating LBD patients with different AT(N) profiles. The results showed that CSF levels of synaptic and neuroaxonal damage biomarkers were significantly increased in AD patients compared to LBD patients and controls. Among LBD patients, those with A+T+ profiles had higher levels of biomarkers for synaptic and neuroaxonal degeneration compared to those with A-T- profiles.

NEUROLOGY (2023)

Editorial Material Clinical Neurology

Advances in Diagnosis and Prognosis of Parkinson Disease

Lucilla Parnetti, Giovanni Bellomo

Summary: The biological definition of Parkinson's disease is still uncertain. Recent advances in fluid biomarkers have been made, but there are limitations in accurately capturing the multiple biological features of the disease.

NEUROLOGY (2023)

Editorial Material Clinical Neurology

Lipoproteins and α-synuclein in cerebrospinal fluid in Parkinson's disease: Dangerous liaisons on the road to neurodegeneration?

Lucilla Parnetti, Giovanni Bellomo, Yaroslau Compta

PARKINSONISM & RELATED DISORDERS (2023)

Article Clinical Neurology

Potential diagnostic value of CSF metabolism-related proteins across the Alzheimer's disease continuum

Silvia Paciotti, Anna Lidia Wojdala, Giovanni Bellomo, Andrea Toja, Elena Chipi, Sander R. R. Piersma, Thang V. V. Pham, Lorenzo Gaetani, Connie R. R. Jimenez, Lucilla Parnetti, Davide Chiasserini

Summary: This study aimed to validate the potential value of four metabolism-related proteins (PKM, ALDO, UCHL1 and FABP3) as new cerebrospinal fluid (CSF) biomarkers for Alzheimer's disease (AD) and their involvement in AD pathogenesis. The results showed that CSF levels of UCHL1 and FABP3, as well as PKM activity, were significantly increased in AD patients, even at the preclinical stage. UCHL1 and FABP3 showed good performance in discriminating early AD patients from controls, while PKM provided the best performance in distinguishing between frontotemporal dementia (FTD) and mild cognitive impairment (MCI).

ALZHEIMERS RESEARCH & THERAPY (2023)

Article Psychology, Clinical

Repeatable Battery for the Assessment of Neuropsychological Status: Italian Normative Data for Older Adults

Elena Chipi, Daniela Fruttini, Nicola Salvadori, Chiara Montanucci, Elisa Siena, Giulia Menculini, Claudia Mazzeschi, Lucilla Parnetti

Summary: This study assessed the impact of age, education, and gender on RBANS subtests, indexes, and total scores in a larger sample of older adults. The obtained normative data showed good concordance with the original norms and suggested that RBANS is not significantly affected by education. The development of a free-to-use Excel spreadsheet to calculate percentiles for individual scores could make RBANS a more precise measure for detecting subtle cognitive deficits in prevention studies.

ARCHIVES OF CLINICAL NEUROPSYCHOLOGY (2023)

No Data Available